{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:16:58Z","timestamp":1791944218412,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B (CHB) is a significant risk factor for liver-related disorders. Hepatic fibrosis staging by liver biopsy in these patients can lead to complications. This study aimed to compare aspartate aminotransferase\/alanine aminotransferase (AST\/ALT) ratio, AST to platelet ratio index (APRI), and fibrosis-4 (FIB-4) with FibroScan results for the evaluation of hepatic fibrosis in CHB patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included patients with CHB referred to the outpatient clinics of Bandar Abbas, Hormozgan, Iran, in 2021. The age and sex of the participants were noted. FibroScan evaluation was done for all subjects. Moreover, AST, ALT, and platelet counts were measured in their blood samples within one month of the FibroScan evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 267 CHB patients evaluated in the present study (mean age: 45.45\u2009\u00b1\u200918.16 years), 173 (64.8%) were male. According to FibroScan results, 65 CHB patients (24.3%) had F1, 53 (19.9%) F2, 38 (14.2%) F3, and 20 (7.5%) F4 liver fibrosis. There was a significant correlation between FibroScan results and the three indices of AST\/ALT ratio, APRI, and FIB-4 (P\u2009&lt;\u20090.001), with the strongest correlation between FibroScan results and APRI (r\u2009=\u20090.682). With an area under the receiver operating characteristic (AUROC) curve of 0.852 (95% confidence interval [CI] 0.807; 0.897, P\u2009&lt;\u20090.001), APRI\u2009\u2265\u20090.527 had the best diagnostic accuracy (77.15%) for the detection of any grade of liver fibrosis. Although the AUROC curve of APRI and FIB-4 was similar (0.864) for distinguishing between F3\/F4 and F0-F2 of liver fibrosis, FIB-4 had the best diagnostic accuracy (82.02%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>APRI can rule out 95.4% of F3\/F4 of liver fibrosis and rule in any grade of liver fibrosis in CHB patients by 90.78%. Therefore, APRI appears to be the best substitute for FibroScan in the assessment of liver fibrosis in patients with CHB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-023-02780-w","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T03:02:41Z","timestamp":1683774161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["AST\/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran"],"prefix":"10.1186","volume":"23","author":[{"given":"Seyed Hamid","family":"Moosavy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parivash","family":"Davoodian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolazim","family":"Nejatizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-5786","authenticated-orcid":false,"given":"Mirza Ali","family":"Nazarnezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"6","key":"2780_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"D Razavi-Shearer","year":"2018","unstructured":"Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The lancet Gastroenterology & hepatology. 2018;3(6):383\u2013403.","journal-title":"The lancet Gastroenterology & hepatology"},{"issue":"4","key":"2780_CR2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"4","key":"2780_CR3","doi-asserted-by":"publisher","first-page":"e35577","DOI":"10.5812\/hepatmon.35577","volume":"16","author":"M Salehi-Vaziri","year":"2016","unstructured":"Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B Virus infection in the General Population of Iran: an updated systematic review and Meta-analysis. Hepatitis monthly. 2016;16(4):e35577.","journal-title":"Hepatitis monthly"},{"issue":"1","key":"2780_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-019-4661-4","volume":"19","author":"MA Behzadi","year":"2019","unstructured":"Behzadi MA, Leyva-Grado VH, Namayandeh M, Ziyaeyan A, et al. Seroprevalence of viral hepatitis A, B, C, D and E viruses in the Hormozgan province southern Iran. BMC infectious diseases. 2019;19(1):1\u201312.","journal-title":"BMC infectious diseases"},{"issue":"1","key":"2780_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-016-9760-3","volume":"11","author":"G Shiha","year":"2017","unstructured":"Shiha G, Ibrahim A, Helmy A, Sarin SK, et al. Asian-Pacific Association for the study of the liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatology international. 2017;11(1):1\u201330.","journal-title":"Hepatology international"},{"issue":"4","key":"2780_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/apt.13488","volume":"43","author":"Y Li","year":"2016","unstructured":"Li Y, Huang YS, Wang ZZ, Yang ZR, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Alimentary pharmacology & therapeutics. 2016;43(4):458\u201369.","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"3","key":"2780_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti A, Boursier J, Castera L, Cazzagon N, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20132021 update. Journal of hepatology. 2021;75(3):659\u201389.","journal-title":"Journal of hepatology"},{"issue":"2","key":"2780_CR8","doi-asserted-by":"publisher","first-page":"e23640","DOI":"10.1002\/jcla.23640","volume":"35","author":"K Liu","year":"2021","unstructured":"Liu K, Qin M, Tao K, Liang Z, et al. Identification and external validation of the optimal FIB-4 and APRI thresholds for ruling in chronic hepatitis B related liver fibrosis in tertiary care settings. Journal of clinical laboratory analysis. 2021;35(2):e23640.","journal-title":"Journal of clinical laboratory analysis"},{"issue":"4","key":"2780_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5114\/ceh.2020.102157","volume":"6","author":"K Metwally","year":"2020","unstructured":"Metwally K, Elsabaawy M, Abdel-Samiee M, Morad W, Ehsan N, Abdelsameea E. FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients. Clinical and Experimental Hepatology. 2020;6(4):335\u20138.","journal-title":"Clinical and Experimental Hepatology"},{"key":"2780_CR10","doi-asserted-by":"crossref","unstructured":"Badawi R, Soliman H, Ziada D, Elhendawy M, et al. Serum markers as a predictor of hepatic fibrosis compared to fibroscan in chronic hepatitis B infected egyptian patients: a cross-sectional study. The Open Biomarkers Journal. 2020;10(1).","DOI":"10.2174\/1875318302010010069"},{"key":"2780_CR11","doi-asserted-by":"crossref","unstructured":"Yue W, Li Y, Geng J, Wang P, Zhang L. Aspartate aminotransferase to platelet ratio can reduce the need for transient elastography in chinese patients with chronic hepatitis B. Medicine. 2019;98(49).","DOI":"10.1097\/MD.0000000000018038"},{"key":"2780_CR12","doi-asserted-by":"crossref","unstructured":"Sha FR, Pk MU, Abuelezz NZ, Pervin R, et al. Investigating the efficiency of APRI, FIB-4, AAR and AARPRI as noninvasive markers for predicting hepatic fibrosis in chronic hepatitis B patients in Bangladesh. The Open Microbiology Journal. 2019;13(1).","DOI":"10.2174\/1874285801913010034"},{"issue":"3","key":"2780_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/09674845.2018.1459147","volume":"75","author":"J Lee","year":"2018","unstructured":"Lee J, Kim MY, Kang SH, Kim J, et al. The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection. British Journal of Biomedical Science. 2018;75(3):128\u201332.","journal-title":"British Journal of Biomedical Science"},{"issue":"11","key":"2780_CR14","first-page":"20876","volume":"8","author":"D Ding","year":"2015","unstructured":"Ding D, Li H, Liu P, Chen L, et al. FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B. International Journal of Clinical and Experimental Medicine. 2015;8(11):20876.","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"1","key":"2780_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"EASL-ALEH Clinical Practice Guidelines","year":"2015","unstructured":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237\u201364.","journal-title":"J Hepatol"},{"issue":"6975","key":"2780_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/bmj.310.6975.298","volume":"310","author":"DG Altman","year":"1995","unstructured":"Altman DG, Bland JM. Statistics notes: the normal distribution. Bmj. 1995;310(6975):298.","journal-title":"Bmj"},{"issue":"4","key":"2780_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jhep.2015.11.012","volume":"64","author":"WR Kim","year":"2016","unstructured":"Kim WR, Berg T, Asselah T, Flisiak R, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. Journal of hepatology. 2016;64(4):773\u201380.","journal-title":"Journal of hepatology"},{"key":"2780_CR18","unstructured":"World Health O. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15: World Health Organization; 2015."},{"issue":"1","key":"2780_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.15171\/bi.2015.05","volume":"5","author":"M Abdollahi","year":"2015","unstructured":"Abdollahi M, Pouri A, Ghojazadeh M, Estakhri R, Somi M. Non-invasive serum fibrosis markers: a study in chronic hepatitis. BioImpacts: BI. 2015;5(1):17.","journal-title":"BioImpacts: BI"},{"issue":"1","key":"2780_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-021-02038-3","volume":"21","author":"B Amernia","year":"2021","unstructured":"Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST\/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC gastroenterology. 2021;21(1):1\u20137.","journal-title":"BMC gastroenterology"},{"issue":"07","key":"2780_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.53350\/pjmhs22167306","volume":"16","author":"M Javed","year":"2022","unstructured":"Javed M, Iqbal J, Aslam MI, Shahzad M, Khan ZA, Yar AA. Compare the efficacy of Aspartate aminotransferase to platelet index (APRI) and FIB-4 with transient elastography: FibroScan in patients with chronic Hepatitis C. Pakistan Journal of Medical & Health Sciences. 2022;16(07):306-.","journal-title":"Pakistan Journal of Medical & Health Sciences"},{"key":"2780_CR22","first-page":"S556-S7","volume":"113","author":"D Alhankawi","year":"2018","unstructured":"Alhankawi D, HunJung K, Sharma S, Park J. Transient elastography (Fibroscan) compared to FIB-4, APRI, and AST\/ALT ratio for Assessment of significant liver fibrosis in patients with chronic Hepatitis C: 989. Official journal of the American College of Gastroenterology| ACG. 2018;113:S556-S7.","journal-title":"ACG"},{"issue":"5","key":"2780_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.dld.2007.10.019","volume":"40","author":"M Yoneda","year":"2008","unstructured":"Yoneda M, Mawatari H, Fujita K, Endo H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Digestive and Liver Disease. 2008;40(5):371\u20138.","journal-title":"Digestive and Liver Disease"},{"issue":"4","key":"2780_CR24","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","volume":"134","author":"M Friedrich\u2013Rust","year":"2008","unstructured":"Friedrich\u2013Rust M, Ong MF, Martens S, Sarrazin C, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960\u201374.","journal-title":"Gastroenterology"},{"issue":"6","key":"2780_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/jgh.12519","volume":"29","author":"KQ Shi","year":"2014","unstructured":"Shi KQ, Tang JZ, Zhu XL, Ying L, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. Journal of gastroenterology and hepatology. 2014;29(6):1149\u201358.","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"7","key":"2780_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3748\/wjg.v27.i7.641","volume":"27","author":"LL Huang","year":"2021","unstructured":"Huang LL, Yu XP, Li JL, Lin HM, et al. Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2021;27(7):641\u201353.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2780_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World journal of gastroenterology: WJG. 2014;20(2):475.","journal-title":"World journal of gastroenterology: WJG"},{"key":"2780_CR28","doi-asserted-by":"crossref","unstructured":"Chon YE, Choi EH, Song KJ, Park JY, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. 2012.","DOI":"10.1371\/journal.pone.0044930"},{"issue":"3","key":"2780_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/gut.2005.069153","volume":"55","author":"J Foucher","year":"2006","unstructured":"Foucher J, Chanteloup E, Vergniol J, Castera L, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3):403\u20138.","journal-title":"Gut"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02780-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T03:03:09Z","timestamp":1683774189000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02780-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02780-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was given ethical approval by the Ethics Committee of Hormozgan University of Medical Sciences (IR.HUMS.REC.139.344) and complies with the statements of the Declaration of Helsinki. Written informed consent was obtained from all the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"145"}}